EAEU registration confirmation is filed no earlier than 260 working days before expiry. Without it the certificate is invalid


When the validity period of a registration certificate nears its end, the applicant must file an application for confirmation of registration of the medicinal product: no earlier than 260 working days before the end of the period and no later than the date it ends. This is set by the Rules for Registration and Regulatory Review of Medicines for Medical Use, approved by Decision of the Council of the Eurasian Economic Commission (EEC) No. 78 of 3 November 2016 (hereinafter Rules No. 78). If the registration holder has not filed the application before the end of the period, the registration certificate is deemed invalid.
The confirmation procedure must not exceed 80 working days in the reference state (the member state of the Eurasian Economic Union, EAEU, whose authority prepares the assessment report) and 50 working days in each state of recognition, whose authority reviews that report. The time the applicant spends answering requests is not counted in these periods.

Before 1 January 2026, confirmation under 61-FZ

Under Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (hereinafter 61-FZ), in the edition of 23 July 2025, a product registered for the first time received a registration certificate for five years, and after that period an indefinite registration certificate was issued on condition that state registration was confirmed. The application was sent through the unified portal no earlier than 180 days before the registration certificate expired and no later than the end of the period. The edition of 23 July 2025 was in force on 5 January 2026.
Confirmation took no more than 40 working days from the date the application was sent. The regulatory review of the benefit-risk balance took no more than 30 working days. The response to a request of the authorized federal body was allowed no more than 90 working days, and the response to a request of the expert institution no more than 60 working days. Response time was not counted in the confirmation period.
The ground for refusal was a conclusion of the federal body that the risk of harm to human or animal health exceeded the efficacy of the product. Circulation of the product was not suspended during the procedure. If registration was not confirmed when a five-year registration certificate expired, that was a ground for cancelling the state registration.

Now, confirmation under Rules No. 78

From 1 January 2026, for medicines for medical use, the 61-FZ provisions on confirmation of state registration and on cancellation of registration for non-confirmation no longer apply, nor do the other provisions listed in Federal Law No. 1-FZ of 30 January 2024 (hereinafter 1-FZ). Paper registration certificates and duplicate registration certificates for such products are not issued from 1 January 2026. 1-FZ makes no exception for confirmation applications filed before 1 January 2026. The transitional provisions of 1-FZ concern state registration under applications filed before 1 January 2021, bringing products into line with EAEU acts (dossier alignment) by 31 December 2025, and the sale of products not brought into line until the end of their shelf life.
Confirmation of registration is governed by Rules No. 78 in the edition of 26 November 2025 (Table 1). Until 31 December 2025, confirmation of registration of a product registered under national law and not brought into line with EAEU requirements was determined by the legislation of the member states.

Table 1. Confirmation of registration of a medicinal product for medical use before and after 1 January 2026

ParameterBefore (61-FZ, edition of 23 July 2025)Now (Rules No. 78, edition of 26 November 2025)
When to file the applicationNo earlier than 180 days before the registration certificate expires and no later than the end of the periodNo earlier than 260 working days before the registration certificate expires in the reference state and no later than the expiry date
Procedure periodNo more than 40 working daysNo more than 80 working days in the reference state and 50 in each state of recognition
Applicant’s response timeNo more than 90 working days for a request of the federal body and no more than 60 for a request of the expert institutionNo more than 90 working days for missing materials and no more than 90 for a consolidated request
If the application is not filedGround for cancelling the registrationThe registration certificate is deemed invalid
Grounds for refusalThe risk of harm to health exceeds efficacyGrounds under Rules No. 78 (section «Why confirmation is refused»)
State fee for confirmation (Russia)172,000 rubles for state registration under 61-FZ (under the Tax Code)207,000 rubles for registration under EAEU law (under the Tax Code)
State fee for issuing the registration certificate (Russia)10,000 rubles for state registration under 61-FZ (under the Tax Code)10,000 rubles for registration under EAEU law (under the Tax Code)

The abolition of confirmation under 61-FZ applies only to medicines for medical use. For veterinary medicinal products, 61-FZ in the edition of 4 August 2026 sets a period of no more than 33 working days from the date the application is accepted. The state fee for confirming the registration of a veterinary medicinal product is 70,000 rubles under the Tax Code.

Procedure and periods of confirmation

Registration is confirmed on the basis of a re-evaluation of the benefit-risk balance carried out by the authorized body (expert organization) of the reference state, which prepares an assessment report on the product. The stages and periods are given in Table 2. The applicant files applications in all member states where the product is registered. The confirmation date for all these states is determined by the date of registration in the reference state under the mutual recognition procedure or the decentralized procedure. While the procedure is under way, the product may circulate on the territory of the EAEU.

Table 2. Stages and periods of confirmation of registration

StagePeriod
Access of the states of recognition to the dossier through the integrated systemNo more than 5 working days from the date the documents are filed
Application and documents to each state of recognitionNo later than 14 working days from the date the application is filed in the reference state
Check of the dossier for completeness, a complete set of documents and correct formatting10 working days from the date the application is filed
Applicant’s response to remarks on the set of documentsNo more than 90 working days; not counted in the confirmation period
Assessment of the applicant’s response to remarks on the set of documentsNo more than 5 working days from the date the response is received
Preliminary assessment report or draft requestWithin 30 working days from the start of the substantive regulatory review
Reasoned request of a state of recognitionNo later than 20 working days from the date the preliminary report is received
Consolidated request to the applicantMay be sent no later than 10 working days from the date the remarks or the agreement of the states of recognition are received
Applicant’s response to the consolidated requestNo more than 90 working days; not counted in the confirmation period
Final assessment reportNo more than 20 working days to consider the response and prepare the report
Conclusion of the state of recognition on whether the report can be recognizedNo more than 20 working days from the date the report is received
Issue of the indefinite registration certificateNo more than 10 working days from the date the assessment report is received
Consideration of disagreements by the Expert Committee for MedicinesNo more than 60 calendar days

The applicant’s two responses (90 working days each) are not counted in the 80- and 50-working-day periods and together may add up to 180 working days.

How the reference state and the states of recognition agree on the report

If a state of recognition disagrees with the conclusions of the preliminary report on the benefit-risk balance, or requires changes to the Summary of Product Characteristics (SmPC), the package leaflet, packaging mock-ups or other dossier documents, it sends a reasoned request to the reference state. The regulatory review in the reference state is suspended until additional remarks or information on agreement are received from all states of recognition. The authorities of the member states taking part in the procedure may hold consultations to agree on the final report.
After the final report, the authorized body (expert organization) of the state of recognition draws up a conclusion on whether the report can be recognized. If the report cannot be recognized, this conclusion with its justification is sent to the applicant and to the Expert Committee. The Expert Committee considers the disagreements. The authorized body of the state of recognition refuses confirmation if, after the disagreements are settled in the Expert Committee, it is established that the report of the reference state cannot be recognized for the reasons listed in the section «Why confirmation is refused». If the benefit-risk balance is assessed positively, the indefinite registration certificate is issued by the reference state and by each state of recognition.

Which documents to file

The applicant submits to the authorized body (expert organization) of the reference state an application in the established form, documents confirming payment of the fee (state fee) and Modules 1 and 2 of the registration dossier. If registration is confirmed on a dossier brought into line with EAEU requirements (dossier alignment) that carries post-registration obligations (post-registration measures under Rules No. 78), the authorized body (expert organization) may also request Modules 1 and 3 and, where necessary, Modules 4 and 5.
No later than 14 working days from the date the application is filed in the reference state, the applicant submits to the authorized body (expert organization) of each state of recognition an application, documents confirming payment under the legislation of that state, and Module 1. If the legislation of the state of recognition so provides, the SmPC, the package leaflet and packaging mock-ups in the state language are added.

Why confirmation is refused

The grounds for refusing confirmation are listed in Rules No. 78. One of them is the persistence of serious health risks at the time of confirmation.
It covers these cases:
a proven unfavorable benefit-risk balance or an identified lack of therapeutic efficacy when the conditions of use described in the approved SmPC are followed;
facts from pharmacovigilance data indicating an unfavorable balance (including a significant excess of the reporting frequency of adverse reactions over the data in the SmPC);
a qualitative or quantitative composition of the product that does not match the declared one, or repeated non-compliance of the quality of the product during its circulation on the EAEU market with the quality declared at registration;
unreliable dossier data or dossier data that have not been updated.

Other grounds: the registration holder has not remedied the remarks or has not submitted a response to the regulatory review questions within the time allowed; the registration holder has not met its pharmacovigilance obligations or the obligations connected with conditional registration.
The authorized body (expert organization) of the reference state rejects the application if the missing materials are not submitted in time, payment of the fee (state fee) is not confirmed, or the application is filed after the filing deadline. If the applicant does not answer the consolidated request in time, the regulatory review and the confirmation of registration are terminated. If the applicant has accepted the proposals of the authorities to change the SmPC, the package leaflet, packaging mock-ups or other dossier documents, those proposals cannot be a ground for refusal.
If facts come to light during confirmation that cast doubt on the reliability of information about manufacture, studies or the organization of the pharmacovigilance system, the authorized body or expert organization of the reference state initiates an inspection by the pharmaceutical inspectorate. The Good Pharmacovigilance Practice Rules of the Eurasian Economic Union (GVP) were approved by Decision of the EEC Council No. 87 of 3 November 2016 (hereinafter the GVP Rules). Under the GVP Rules, the authorized body of a member state may refuse registration, confirmation of registration (re-registration) or other registration-related procedures if the results of a pre-registration inspection of the pharmacovigilance system raise concern about the registration holder’s ability to meet the requirements for the system.

What is checked in the dossier during confirmation

The authorized body (expert organization) of a member state analyzes whether the registration holder has met the conditions of registration (post-registration measures under Rules No. 78), if they were applied to it. If new safety and efficacy data appear, the conditions of registration may be changed and new ones may be set. The body also checks whether the registration holder meets its obligations to keep the product information up to date in light of current scientific knowledge.
If the authorized body (expert organization) of the reference state finds during confirmation that the registration holder has not met these conditions and obligations for objective reasons and the dossier must be changed, then after the reference state’s positive conclusion on confirmation the registration holder starts the procedure for variations to the normative document on quality, the SmPC, the package leaflet and the risk management plan (RMP). The period for starting this procedure is no more than 120 working days from the date of the reference state’s request. Variations of Type IA, Type IA with immediate notification and Type IB may be made during confirmation without a separate application.
For products approved on an application with initial submission of a full dossier, the RMP is reviewed twice: at confirmation of registration 5 years after registration, and when the first periodic safety update report is submitted after re-registration (under the GVP Rules).

For what period the registration certificate is issued

The validity period of the registration certificate of a product registered for the first time in the reference state is five years; after that period an indefinite registration certificate is issued on condition that registration is confirmed. Based on pharmacovigilance data, and also taking into account the failure to meet the conditions of registration for objective reasons and the admissibility of Type IA, Type IA with immediate notification and Type IB variations during confirmation, the authorized body of the reference state may, on the results of the regulatory review, decide to issue the registration certificate for five years, with registration to be confirmed again when that period ends.
When a dossier is brought into line with EAEU requirements (dossier alignment), an indefinite registration certificate is issued without confirmation under Rules No. 78 in two cases:
the product has been registered under the legislation of a member state for five years or more and is intended to circulate only on the market of that member state;
the product is registered under the legislation of the member states named in the application for alignment with EAEU requirements and has been registered on the market of the reference state for five years or more (the procedure of bringing the registration dossier into line with EAEU requirements).

If during alignment the reference state set one or more additional requirements for the product, a registration certificate for five years is issued in each of these two cases. For a product registered for the first time, the condition of circulation on the market of a single member state is not set in Rules No. 78, either in the provision on the validity period of the registration certificate or in the section on confirmation of registration.

What to do

Put the filing deadline for each registration certificate in the calendar. File the application no earlier than 260 working days before the registration certificate expires in the reference state and no later than that date. An application filed after the end of the period is rejected, and the registration certificate is deemed invalid. For each product of the company, record the expiry date of the registration certificate and the date from which the application can be filed. Add the 14 working days for applications to the states of recognition and the two periods of 90 working days for the applicant’s responses.
Check the dossier against the conditions of registration. Check that the post-registration measures under Rules No. 78 have been met, if they applied to the product, and that the SmPC and the package leaflet are up to date. Complete any variation procedures already started and identify the Type IA, Type IA with immediate notification and Type IB variations that can be made during confirmation.
Check pharmacovigilance data against the grounds for refusal. Compare the reporting frequency of adverse reactions in the pharmacovigilance data with the SmPC, make sure the pharmacovigilance obligations are met, and check whether the RMP review under the GVP Rules has been prepared.
File the application and pay the state fee. The reference state receives the application in the established form, documents confirming payment and Modules 1 and 2; each state of recognition receives the application, documents confirming payment and Module 1. In Russia the state fee is 207,000 rubles for confirmation and 10,000 rubles for issuing the registration certificate. Fee amounts in other member states are determined by their legislation.
Assign people responsible for requests. The authorized body (expert organization) of the reference state may send the applicant a consolidated request in written or electronic form. A request for missing materials is sent through telecommunication channels and is deemed received after one day from the date it is sent. Name the employees who receive requests and divide the answers among the quality, pharmacovigilance and registration departments. If a response is not submitted in time, confirmation of registration is terminated.


Regulatory framework:

1. Decision of the EEC Council No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» (as amended on 26 November 2025)
2. Decision of the EEC Council No. 87 of 3 November 2016 «On Approval of the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union» (as amended on 19 May 2022)
3. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended on 23 July 2025 for the section on the period before 1 January 2026; current edition as amended on 4 August 2026)
4. Federal Law No. 1-FZ of 30 January 2024 «On Amendments to the Federal Law ‘On the Circulation of Medicines’ and Articles 1 and 4 of the Federal Law ‘On Amendments to the Federal Law «On the Circulation of Medicines» and the Federal Law «On Amendments to the Federal Law ‘On the Circulation of Medicines’»‘» (as amended on 28 December 2025)
5. Tax Code of the Russian Federation, Part Two (as amended on 4 August 2026)

This page in Russian→